Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen + Dexamethasone in RRMM (HORIZON)
NCT02963493Phase 2Completed
- Sponsor
- Oncopeptides AB
- Start
- Dec 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 4
01
Overview
A Phase 2 trial of melphalan flufenamide in multiple myeloma (MM), sponsored by Oncopeptides AB. Started Dec 2016; status: completed.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02963493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963493.